DE、NE方案治疗晚期乳腺癌的临床对比观察

A Comparison of DE and NE Regimen in Patients with Advanced breast Cancer

目的观察多西紫杉醇联合表阿霉素(DE方案)与诺维本联合表阿霉素(NE方案)治疗晚期乳腺癌的疗效及不良反应.方法对64例晚期乳腺癌分别采用DE方案、NE方案治疗.DE方案组:多西紫杉醇75 mg/m2,静脉滴注,第1天;表阿霉素40～50 mg/m2,静脉注射,第2天.NE方案组:诺维本25 mg/m2,静脉滴注,第1、8天;表阿霉素用法同DE组.每21天为1个周期.结果DE方案组总有效率(61.8%,21/34)和复治有效率(57.9%,11/19)均分别高于NE方案组(40.0%,12/30;33.3%,6/18);DE方案组中位疾病进展时间(9.2个月)长于NE方案组(7.2个月),P＜0.05;DE方案组和NE方案组中位生存期分别为18个月和17个月(P＞0.05).不良反应以骨髓抑制、胃肠道反应和静脉炎为主.结论DE方案及NE方案对晚期乳腺癌均有较好的疗效,DE方案对复治患者疗效较好,可作为晚期乳腺癌一线化疗方案和复治晚期乳腺癌的解救方案.

Objecyive To evaluate the efficacy and adverse reactions of docetaxel-epirubicin（DE regimen） and vinorelbineepirubicin（NE regimen） in the treatment of advanced breast cancer. Methods Sixty-four patients of advanced breast cancer. Patients received DE and NE.Docetaxel 75 mg/m^2 by infusion on lday, followed by Epirubicin 40-50 mg/m^2 by infusion on 2day in DE. Vinorelbine 25 mg/m2 by infusion on day 1,8 in NE,and epirubicin was same to NE. The treatment was repeated every 3 week. Results The objective overall response rate was 61.8% （21/34） and the reteated patients response rate was 57.9% （11/19） in DE. The overall response rate was 40.0% （12/30） and the reteated patients response rate was 33.3% （6/18） in NE. The median time to progression was 9.2 months in DE had a higher 7.2 months in NE with significant difference（P 〈 0.05）. Overall the median survival （MST） was 18 months and 17 months in DE and NE（P 〉0.05）. The main toxicity was myelosuppression,gastrointestinal tract reaction and phlebitis. Conelusion The combination of docetaxel-epirubicin and vinorelbine-epirubicin was found to be effective in chemotherapy patients with advanced breast cancer. The repeated theraputic efficacy of DE was superior to NE, It could be regarded as the first chemotherapy treatment and rescue treatment.